Table 3.

Cumulative HCC risk by risk category of HBV-HCC models.

Models	HCC risk at 3 years (%, 95% CI)	HCC risk at 5 years (%, 95% CI)
REACH-B
Low	2.5% (1.0–2.4)	3.0% (2.1–4.2)
Intermediate	2.5% (1.6–3.8)	5.2% (3.7–7.3)
High	2.6% (0.4–17.2)	2.6% (0.4–17.2)
PAGE-B
Low	0% (n.a.)*	0% (n.a.)*
Intermediate	0.8% (0.4–1.5)	1.9% (1.2–3.1)
High	4.5% (3.5–5.9)	6.5% (5.0–8.3)
mPAGE-B
Low	0% (n.a.)*	0% (n.a.)*
Intermediate	1.0% (0.4–2.2)	1.4% (0.7–2.9)
High	3.0% (2.2–4.3)	6.6% (5.1–8.5)
CU-HCC
Low	0.6% (0.2–1.6)	1.1% (0.5–2.4)
Intermediate	1.5% (0.7–3.1)	4.2% (2.5–6.8)
High	3.9% (2.7–5.7)	7.3% (5.4–10.0)
HCC-RESCUE
Low	0% (n.a.)*	0.2% (0–1.4)
Intermediate	1.3% (0.8–2.3)	3.4% (2.4–4.8)
High	4.0% (2.9–5.7)	6.9% (5.1–9.2)
CMAD
Low	0% (n.a.)*	0.2% (0.0–1.6)
Intermediate	1.2% (0.7–2.0)	3.1% (2.2–4.3)
High	5.0% (3.5–7.2)	8.3% (6.1–11.2)
APA-B
Low	1.0% (0.6–1.8)	2.2% (1.5–3.4)
Intermediate	6.4% (0.4–11.1)	12.8% (8.0–18.1)
High	13.6% (7.2–24.8)	15.9% (8.7–28.1)
REAL-B
Low	0% (n.a.)*	0% (n.a.)*
Intermediate	1.3% (0.8–2.2)	3.1% (2.2–4.5)
High	6.5% (4.4–9.6)	10.7% (7.6–14.8)
AASL-HCC
Low	0% (n.a.)*	0% (n.a.)*
Intermediate	1.0% (0.6–1.7)	2.5% (1.8–3.7)
High	5.2% (3.5–7.6)	9.5% (7.0–12.9)
RWS-HCC
Low	0.3% (0.1–1.0)	1.2% (0.6–2.2)
High	4.1% (3.0–5.7)	7.4% (5.6–9.6)

Cox-proportional hazard models were used to calculate HCC risk at 3 years and 5 years. AASL-HCC, age, albumin, sex, liver cirrhosis-HCC; AFP, alpha-fetoprotein; APA-B, age, platelet, AFP; CAMD, cirrhosis, age, male sex, and diabetes mellitus; CU-HCC, Chinese University HCC; HCC, hepatocellular carcinoma; HCC-RESCUE, HCC-Risk Estimating Score in CHB patients Under Entecavir; mPAGE-B, modified PAGE-B; REACH-B, Risk estimation for hepatocellular carcinoma in chronic hepatitis B; REAL-B, Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score; RWS-HCC, Real-world risk score for hepatocellular carcinoma.

^*n.a.: not applicable due to no case in the category.